Regeneron enters venture investing with $500M, poaches senior partner from ARCH
Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per year for five years, it said Monday morning. The drugmaker is the exclusive limited partner for the fund, which launched this month under the name